About: A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice
Creator	Kayali, Ghazi El-Shesheny, Rabeh Gomaa, Mokhtar Kandeil, Ahmed Mahmoud, Sara Mostafa, Ahmed Shehata, Mahmoud Webby, Richard Ali, Mohamed
Source	Medline; PMC
abstract	Middle East Respiratory Syndrome Coronavirus (MERS-CoV) became a global human health threat since its first documentation in humans in 2012. An efficient vaccine for the prophylaxis of humans in hotspots of the infection (e.g., Saudi Arabia) is necessary but no commercial vaccines are yet approved. In this study, a chimeric DNA construct was designed to encode an influenza A/H1N1 NA protein which is flanking immunogenic amino acids (aa) 736–761 of MERS-CoV spike protein. Using the generated chimeric construct, a novel recombinant vaccine strain against pandemic influenza A virus (H1N1pdm09) and MERS-CoV was generated (chimeric bivalent 5 + 3). The chimeric bivalent 5 + 3 vaccine strain comprises a recombinant PR8-based vaccine, expressing the PB1, HA, and chimeric NA of pandemic 2009 H1N1. Interestingly, an increase in replication efficiency of the generated vaccine strain was observed when compared to the PR8-based 5 + 3 H1N1pdm09 vaccine strain that lacks the MERS-CoV spike peptide insert. In BALB/c mice, the inactivated chimeric bivalent vaccine induced potent and specific neutralizing antibodies against MERS-CoV and H1N1pdm09. This novel approach succeeded in developing a recombinant influenza virus with potential use as a bivalent vaccine against H1N1pdm09 and MERS-CoV. This approach provides a basis for the future development of chimeric influenza-based vaccines against MERS-CoV and other viruses.
has issue date	2019-12-02(xsd:dateTime)
bibo:doi	10.3390/pathogens8040281
bibo:pmid	31810359
has license	cc-by
sha1sum (hex)	02a29bd2f39ecdbbb5e51a003c0bc7818029f384
schema:url	https://doi.org/10.3390/pathogens8040281
resource representing a document's title	A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice
has PubMed Central identifier	PMC6963271
has PubMed identifier	31810359
schema:publication	Pathogens
resource representing a document's body	covid:02a29bd2f39ecdbbb5e51a003c0bc7818029f384#body_text
is schema:about of	named entity 'bivalent' named entity 'replication' named entity 'pandemic' named entity 'Mice' named entity 'MICE' named entity 'PEPTIDE' named entity 'INFECTION' named entity 'HUMAN HEALTH' named entity 'VIRUSES' named entity 'MANUSCRIPT' named entity 'VACCINE' named entity 'INFLUENZA A' named entity 'REPLICATION' named entity 'USE' named entity 'SPIKE PROTEIN' named entity 'SOFTWARE' named entity 'SPECIFIC' named entity 'BALB' named entity 'ENCODE' named entity 'IMMUNOGENIC' named entity 'APPROVED' named entity 'A.M.' named entity 'RECOMBINANT' named entity 'CHIMERIC' named entity 'NECESSARY' named entity 'VACCINE' named entity 'CARRYING' named entity 'WRITING' named entity 'GENERATED' named entity 'DEVELOPMENT' named entity 'PROVIDES' named entity 'INFLUENZA A' named entity 'BALB' named entity 'PEPTIDE' named entity 'MERS-COV' named entity 'NOVEL' named entity 'EFFICIENCY' named entity 'THREAT' named entity 'DNA CONSTRUCT' named entity 'COMMERCIAL' named entity 'FINAL' named entity 'LACKS' named entity 'AMINO ACIDS' named entity 'DEVELOPING' named entity 'BASED' named entity 'OBSERVED' named entity 'VACCINES' named entity 'AUTHORS' named entity 'PREPARATION' named entity 'INSERT' named entity 'ORIGINAL' named entity 'H1N1' named entity 'APPROACH' named entity '736' named entity 'SUCCEEDED' named entity 'NEUTRALIZING ANTIBODIES' named entity 'COMPARED' named entity 'M.S.' named entity 'CONSTRUCT' named entity 'INFLUENZA VIRUS' named entity 'PB1' named entity 'INDUCED' named entity 'EFFICIENT' named entity 'IMMUNOGENIC' named entity 'REVISED' named entity 'INACTIVATED' named entity 'PR8' named entity 'FUNDING' named entity 'USING' named entity 'ANALYSIS' named entity 'VACCINE STRAIN' named entity 'SUPERVISION' named entity 'PROTEIN '

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software